Avalo Therapeutics, Inc.
AVTX
$19.39
-$0.06-0.31%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 59.00K | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 59.00K | -- | -- |
| Cost of Revenue | 19.03M | 10.15M | 8.78M | 9.99M | 10.66M |
| Gross Profit | -19.03M | -10.15M | -8.73M | -9.99M | -10.66M |
| SG&A Expenses | 8.10M | 6.85M | 6.53M | 5.58M | 5.24M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.52M | 20.90M | 19.80M | 19.20M | 19.32M |
| Operating Income | -31.52M | -20.90M | -19.74M | -19.20M | -19.32M |
| Income Before Tax | -36.34M | -19.62M | -13.59M | -30.61M | -20.75M |
| Income Tax Expenses | 18.00K | 12.00K | 130.00K | 11.00K | 16.00K |
| Earnings from Continuing Operations | -36.36M | -19.63M | -13.72M | -30.63M | -20.77M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -36.36M | -19.63M | -13.72M | -30.63M | -20.77M |
| EBIT | -31.52M | -20.90M | -19.74M | -19.20M | -19.32M |
| EBITDA | -31.50M | -20.88M | -19.73M | -19.14M | -19.18M |
| EPS Basic | -0.83 | -0.98 | -0.75 | -2.19 | -1.92 |
| Normalized Basic EPS | -0.52 | -0.61 | -0.47 | -1.37 | -1.20 |
| EPS Diluted | -0.83 | -0.98 | -0.75 | -2.19 | -1.92 |
| Normalized Diluted EPS | -0.52 | -0.61 | -0.47 | -1.37 | -1.20 |
| Average Basic Shares Outstanding | 43.60M | 20.11M | 18.23M | 14.00M | 10.83M |
| Average Diluted Shares Outstanding | 43.60M | 20.11M | 18.23M | 14.00M | 10.83M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |